Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (794)	11/18/2000 8:56:27 PM
From: scaram(o)uche	Respond to of 1475

>> any idea why BTRN still has such a low market cap? << 1. long-term issues with xeno.... impatience of investors, and technical hurdles that need to be addressed. 2. MEDI 3. MEDI 4. difficulty with the concept of controlled graft-versus-host disease to fight lymphoid malignancies, and conceptual grapling with making it a "product". 5. MEDI 6. lack of appreciation for IP of SCS. The independent company, yet to be named, will be public and IMO, at a monstrous capitalization some day. It's the "some day" that is intolerable to some investors, and MEDI's insights and speed aren't taking up the slack. Let that be a lesson for those who might consider a collaboration with MEDI. Don't. There are three routes to huge success with BTRN, and a couple of lesser ones. There's only one thing, however, to hang your "tomorrow" hat on..... 507.

To: Harold Engstrom who wrote (794)	11/18/2000 9:07:36 PM
From: scaram(o)uche	Respond to of 1475

>> My equity holdings never seem to suffer from irrational exuberance. << Me too..... I rarely catch them. When I do, I most often get off way, way too early. TTP warrants (no longer existent) and KDUS were recent 20 bag exceptions. But..... I'm most often in the "exuberance-constrained" situation with you. OTOH, I almost never lose money. Therefore started to position trade, and it's been pop after pop. Highly recommended for those who know the sector and also have a good supply of Zantac.

To: Harold Engstrom who wrote (794)	11/19/2000 10:05:50 AM
From: Mark Bong	Respond to of 1475

Harold, as you probably know, there has been a lot of selling going on with BTRN, and this has surely depressed the stock price. Health Care Ventures (HCV) owned about 1.5MM shares via HCV I, 775,000 shares via HCV II, and 228,000 shares via HCV III for a grand total of 2,500,000 shares. Their ownership was about 18-20% of the entire company (http://www.sec.gov/Archives/edgar/data/880259/0000912057-00-014174.txt), HCV has sold over 1.5MM shares this year beginning in late June and through September 28. (http://biz.yahoo.com/t/b/btrn.html). HCV’s selling, of course, has put tremendous pressure on the stock price, and we painfully are aware of that. We can assume here that the depressed stock price is a reflection of poor general market conditions (meaning that we are in a bear market) exacerbated by large institutional selling in BTRN. I believe that HCV’s selling has continued up to the present time. The good news is that they must be out or nearly out by now. I would expect that the new buyers would want to see some good returns, especially if they are institutions, so we might see some pumping late this year or next year. I listened to a presentation given by Eliot Lebowitz a few months ago. He indicated that MEDI would have exciting announcements regarding advancing MEDI 507 "prior" to the end of the year. So far, those announcements have been pretty lame. The year is not over yet, but as Richard said, it would be nice to see MEDI step up to the microphone and make some exciting comments. Take care. Mark